Full-Time

Strategic Sourcing Director

Posted on 5/8/2026

ENOVIS

ENOVIS

1,001-5,000 employees

Global medical technology company; orthopedic solutions

No salary listed

No H1B Sponsorship

Dallas, TX, USA

Remote

Dallas, TX preferred; remote within the U.S. option available.

Category
Operations & Logistics (1)
Required Skills
NetSuite
Market Research
SAP Products
Oracle
Requirements
  • Minimum of 10 years of experience progressive experience in Sourcing and Procurement, Purchasing, and Supply Inventory planning with a proven ability to lead change.
  • Experience in common Material Requirements Planning systems such as Oracle, SAP, or NetSuite is required.
  • Experience in negotiation and contract development is required.
  • Deep understanding of the end-to-end procurement process; 10+ years of strategic sourcing experience leveraging data to create leading category strategies that generated significant value
  • 5+ years demonstrated success in leading categories and teams within a regulated environment
  • 5+ years demonstrated success of strong global leadership and influencing skills with the ability to build effective relationships with stakeholders and peers that inspire trust, collaboration, and operational excellence
  • Strong analytical acumen and experience influencing senior leaders based on deep supply market knowledge
  • Experience building a new set of capabilities within an organization, passionate about contributing to best-in-class procurement.
  • Ability to effectively lead through change and ambiguity.
  • Strong project management skills with ability to plan tasks, assign and manage resources, remove barriers, manage change, resolve conflict, build consensus, and motivate team members across multiple projects concurrently
  • Excellent communication skills with the ability to tailor messages to the given audience and influence outcomes. Can present information in a clear and concise manner
  • Ability to prioritize, organize and multitask in a flexible, fast-paced, and challenging environment
  • Strong project and process management to execute supply strategy for assigned categories with cross functional teams.
  • Expertise with contract requirements to negotiate critical terms and conditions in line with category strategy.
  • Bachelor’s degree required
Responsibilities
  • Lead the procurement strategies a variety of categories up to and including Resins, Metals, Fabrics, Foam, Chemicals, and Finished Goods. Accountable for over defined spend of global spend across raw materials, finished goods and distributed products for the Medical Segment including both Cardinal and OEM Branded products.
  • Responsible for delivering the planned performance and continually improving the strategies for all assigned categories; leads strategic thinking to develop longer-range category strategies and plans that drive significant value while meeting the business requirements.
  • Delivers on annual goals by leading cross-functional teams using spend data analytics, market research, benchmarks, and cost modeling to identify and leverage high value opportunities that deliver innovative and sustainable value, operational efficiencies, and risk mitigation to the business.
  • Develops and manages a high-performing team of procurement professionals and people leaders in the category management team.
  • Guides team through supplier selection and management, contract negotiation, and drives supply chain optimization and risk mitigation for the assigned supply base.
  • Guides team through development and implementation of sourcing, negotiating, and contracting strategies to achieve category goals.
  • Based on strategy, influences business decisions to enter/exit product lines, drive make/buy decisions and implement supply base optimizations.
  • Demonstrates cross functional leadership to manage senior business stakeholders in a highly matrixed environment and builds relationships that facilitate realization of business value.
  • Enables downstream supplier management through a robust category strategy and aligned contractual structures. Collaborates on critical supplier oversight, securing compliance to contracted terms and relevant socially responsible regulations and policies. Partners with suppliers to drive optimization of supplier performance and harness supplier innovation.
  • Transparently communicates priorities and needs to Procurement and Business leadership.
  • Ensures resourcing and bandwidth to meet the business needs for the assigned category spend.
  • Sets aggressive continuous improvement goals; identifies and leads initiatives in partnership with stakeholders to explore a broad set of value levers to deliver on targets.
Desired Qualifications
  • Master’s degree in Business Administration, Supply Chain Management, or a related field.
  • Professional certifications such as Certified Supply Chain Professional (CSCP) or Certified Professional in Supply Management (CPSM).
  • Experience in a high-growth or technology-driven organization.
  • Familiarity with sustainable sourcing practices and supplier diversity initiatives.
  • Applicants must already have full-time work authorization in the United States, both now and in the future, without requiring sponsorship.

Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Extremities segment achieves 10% organic growth led by double-digit shoulder gains.
  • ARVIS robot deployment starts with South Africa procedure, adoption expands through 2026.
  • BTIG initiates Buy rating with $41 target on new launches in hips and knees.

What critics are saying

  • $1.18B goodwill impairment from LimaCorporate overpayment erodes R&D capital now.
  • Stryker Mako captures 60% US robotic shoulder procedures, blocks ARVIS adoption by 2027.
  • Zimmer Biomet Persona IQ steals Nebula conversions, slows recon growth by mid-2027.

What makes ENOVIS unique

  • Enovis leverages Enovis Growth Excellence system for continuous operational improvements.
  • Enovis offers ARVIS shoulder robot and Augmented Reverse Glenoid System for extremities.
  • Enovis integrates LimaCorporate acquisition to expand reconstructive implant portfolio.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at ENOVIS who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Legal Services

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

32%
Yahoo Finance
Feb 28th, 2026
Enovis reports strong revenue growth and new device uptake despite $1.18B goodwill impairment

Enovis Corporation has reported strong organic revenue growth driven by new product launches, including the Nebula Stem and OrthoDrive Impactor, which have seen rapid market uptake. The medical technology company's devices are gaining traction with surgeons and hospitals. However, Enovis recorded a significant goodwill impairment charge in its fourth quarter and full-year results, affecting its balance sheet. The impairment raises questions about returns from previous acquisitions and future capital allocation strategy. Trading at $25.47, Enovis shares are approximately 44% below the analyst price target of $45.18. The company currently shows a loss of $1.18 billion and trades at a forward price-to-earnings ratio of 25.73 times. Investors are advised to monitor how product adoption and procedure volumes affect future cash flow.

Yahoo Finance
Feb 26th, 2026
Enovis stock jumps 12.6% on strong 2026 earnings forecast despite Q4 revenue miss

Enovis Corporation shares jumped 12.6% in morning trading after the medical technology company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. Whilst quarterly revenue of approximately $576 million missed expectations, adjusted earnings per share of $0.95 beat analyst estimates. The stock surge was driven by Enovis's 2026 earnings guidance of $3.52 to $3.73 per share, with the midpoint significantly exceeding analyst projections. This positive profit outlook overshadowed the revenue shortfall. Enovis shares have experienced high volatility, with 26 moves exceeding 5% over the past year. The stock is down 6.6% year-to-date and trading 38.1% below its 52-week high of $40 from March 2025.

Yahoo Finance
Feb 26th, 2026
Enovis reports $520.6M Q4 loss despite adjusted earnings of 95 cents per share

Enovis Corporation reported a fourth-quarter loss of $520.6 million, or $9.10 per share. The Wilmington, Delaware-based manufacturing and engineering company posted adjusted earnings of 95 cents per share, excluding asset impairment and non-recurring costs. Revenue for the quarter reached $575.8 million. For the full year, Enovis reported a loss of $1.18 billion, or $20.75 per share, on revenue of $2.25 billion.

Yahoo Finance
Jan 23rd, 2026
BTIG initiates Enovis with $41 target as orthopedic tech firm eyes growth from new product launches

Enovis Corporation has received positive analyst coverage, with BTIG initiating a Buy rating and $41 price target on 6 January. The orthopedic care company is expected to see accelerated growth in 2026 driven by new product launches across extremities, hips and knees. BTIG highlighted the company's consistent mid-to-high single-digit organic revenue growth in its Reconstruction and Prevention & Recovery segments. The higher-growth Reconstruction business is expected to drive margins whilst the mature Prevention & Recovery segment delivers steady cash flow. UBS maintained its Buy rating but lowered its price target to $50 from $57, projecting sales of $2.26 billion in 2025, $2.37 billion in 2026 and $2.52 billion in 2027.

TradingView
Dec 10th, 2025
Enovis secures $700M term loan and $1.1B credit facility, extends maturity to 2030

Enovis Corp has entered Amendment No. 3 to its credit agreement on 8 December, extending the loan maturity date to 8 December 2030. The amended agreement provides a revolving credit facility of up to $1.1 billion and a term loan facility of $700 million. The company used term loan proceeds to repay $335 million from its revolving facility. The amendment restructures Enovis's debt arrangements, providing the medical technology company with extended financing flexibility through the end of the decade.

INACTIVE